Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
Pluri will retain its underlying technology and intellectual property while receiving an ownership stake in ZEO.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pluri (PLUR) signed a definitive partnership agreement with ZEO ScientifiX to expand their U.S. regenerative medicine manufacturing and commercial platform. Pluri will grant defined manufacturing technology and know-how rights while retaining ownership of its underlying technology and intellectual property. In exchange, ZEO will initially issue common shares representing 50% of its outstanding common stock immediately following closing.
The agreement provides exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings. The companies intend to broaden offerings through ZEO’s existing physician network and commercial infrastructure, subject to applicable regulatory requirements. Closing is expected in the fourth quarter of 2026, subject to ancillary agreements, certain approvals and delivery of valuations. Neither company requires stockholder approval.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.ZEO will initially issue Pluri common shares representing 50% of outstanding common stock immediately following closing.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Exclusive U.S. Cellav rights provide a route through ZEO’s existing physician network and commercial infrastructure.
- Minor point. Forward-looking: it has not happened yet and may not happen.Underlying technology and intellectual property ownership will remain with Pluri under the rights grant.
- Minor point. Forward-looking: it has not happened yet and may not happen.Broader product offerings and selected clinical programs are planned through combined scientific, manufacturing and commercial capabilities.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Closing expected in the fourth quarter of 2026 depends on ancillary agreements, certain approvals and delivery of valuations.
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned product and development expansion remains subject to applicable regulatory requirements.
News Explained
After closing, Pluri expects ZEO’s financial results to be consolidated into Pluri’s financial statements, subject to applicable accounting requirements; if those conditions are met, Pluri’s reported results would include ZEO’s results, but the release describes this as a future treatment.
Details
Market move: PLUR +20.20% vs previous close. U.S. manufacturing partnership
On Oct 26, the day this news came out, the latest delayed price for PLUR is 20.20% above the previous close. Argus tracked a peak move of +14.4% during the session. Our momentum scanner has recorded 18 alerts for this stock so far that day. The latest delayed price is $1.19. Relative volume is very high at 3.3x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- ZEO ownership
- 50%
- Pluri's ownership at Closing under the transaction terms
- Expected closing
- Fourth quarter of 2026
- Proposed transaction; subject to closing conditions
Previous Partnership Reports
-
Pluri established Cellav and agreed to co-develop skincare for a first-half 2026 launch.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase iii trials medical
warrants financial
consolidated financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure
- Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources.
- Complementary technology and development capabilities: Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion platform.
- Broader product and clinical-development opportunities: The companies intend to expand commercial offerings, including regenerative aesthetics, and combine scientific resources to strengthen and advance selected clinical programs.
- Aligned ownership: The transaction and contemplated additional share exchange will result in Pluri owning
50% of ZEO at Closing following the completion of the applicable transaction steps.
HAIFA, Israel and FORT LAUDERDALE, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri”) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO”) today announced a definitive strategic agreement (“Partnership Agreement”) to expand the parties U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.
ZEO brings an established U.S. biologics business combining scientific and manufacturing capabilities with the infrastructure needed to reach and support physicians. Its existing biologics portfolio, substantial physician network, established sales channel, dedicated marketing department, and educational programming provide a foundation for introducing additional products and expanding commercial operations.
Pluri contributes more than two decades of experience in cell-based research, product development, clinical trials, process scale-up, quality systems, and manufacturing. Its proprietary three-dimensional cell-expansion technology and intellectual property support the development and manufacture of cell-based products and its Cellav Health and Aesthetics Ltd.’s (“Cellav”) regenerative aesthetics portfolio.
Together, the companies intend to connect these complementary capabilities to broaden product offerings, expand commercial reach, and strengthen selected regenerative-development programs, subject to applicable regulatory requirements.
Expanding Opportunities in Regenerative Aesthetics
The Partnership Agreement also provides for exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings. Cellav, Pluri’s wholly owned aesthetics subsidiary, develops cell-derived ingredients and aesthetic products that the companies intend to introduce through ZEO’s commercial platform.
Advanced Product Development
Pluri brings more than two decades of clinical-development expertise, including multinational Phase III trials in muscle recovery following hip-fracture surgery and critical limb ischemia (CLI), supported by extensive scientific and clinical data and an intellectual property portfolio of over 200 patents. By combining Pluri’s accumulated knowledge and development experience with ZEO’s research, manufacturing, and commercial capabilities, the companies aim to develop and bring to market advanced therapeutic products, supported by scientific evidence and informed by extensive clinical data.
Leadership Perspectives
Ian Bothwell, Chief Executive Officer of ZEO ScientifiX commented: “Pluri brings capabilities that are exceptionally valuable to our business: proprietary cell technology, two decades of scientific and clinical experience, and proven expertise in scalable cell manufacturing. We believe combining these strengths with ZEO’s scientific expertise and commercial infrastructure will allow us to expand our product portfolio, accelerate innovation, and pursue opportunities that neither company could address as effectively on its own. We are excited to partner with Pluri and build a stronger platform for the future of regenerative medicine.”
Yaky Yanay, President and Chief Executive Officer of Pluri commented: “ZEO has built something highly valuable: an established U.S. commercial platform with direct access to physicians, an existing advanced product portfolio, and dedicated sales, marketing, and educational capabilities. For Pluri, this creates an important opportunity to connect more than two decades of cell technology, clinical development, and advanced manufacturing expertise with an existing route to market. We believe this partnership can accelerate commercialization, expand our reach in the U.S., and support our ambition to build a growing regenerative medicine business.”
Transaction Overview
Under the Partnership Agreement, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how for associated with its regenerative medicine associated assets, while retaining ownership of its underlying technology and intellectual property. In consideration, ZEO will initially issue shares of its common stock representing
Following closing, ZEO’s financial results are expected to be consolidated into Pluri’s financial statements, subject to applicable accounting requirements.
Closing of the proposed transaction, which is expected to occur in the fourth quarter of 2026 is subject to satisfaction of a number of conditions, including the negotiation of various ancillary agreements, securing certain approvals and the delivery of valuations, as well as other customary closing conditions. The transaction is not subject to stockholder approval by either Pluri or ZEO.
About Pluri
Pluri™ is a biotechnology company advancing cell-based solutions for health and longevity. Powered by its proprietary 3D cell expansion platform, Pluri develops and manufactures innovative cell-based products designed to address significant unmet medical needs and support healthier, longer lives. With decades of expertise in cell science, clinical development and scalable manufacturing, Pluri is building a portfolio of regenerative and longevity-focused solutions while leveraging its technology and manufacturing capabilities through strategic partnerships. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
About ZEO ScientifiX
ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a U.S. biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with established commercial operations. Based at Nova Southeastern University’s Center for Collaborative Research in Davie, Florida, ZEO combines scientific and manufacturing expertise with a substantial physician network, dedicated sales and marketing resources, and physician education infrastructure. Through internal development and strategic partnerships, ZEO seeks to expand its product portfolio and advance regenerative medicine. To learn more, visit www.zeoscientifix.com or follow ZEO on LinkedIn, Facebook and Instagram.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable U.S. securities laws, including statements regarding transaction completion and timing; licensing, ownership, and accounting consolidation; integration; product development and commercialization; clinical programs, and anticipated strategic and financial benefits.
Actual results could differ materially due to risks including failure to complete the transaction; integration challenges; insufficient funding; unsuccessful development, clinical trials, or commercialization; manufacturing and supply issues; competition; and changes in applicable federal and state regulatory requirements. Prior clinical experience does not assure future success.
Additional risks are described in the companies’ respective SEC filings. Neither company undertakes to update forward-looking statements except as required by law.
Contacts
Pluri Investor Relations
investor.relations@pluri-biotech.com
ZEO ScientifiX
investor.relations@zeoscientifix.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/200b1de8-e87f-403d-83cc-f13752007908
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake will Pluri receive under the ZEO ScientifiX partnership?
ZEO will initially issue Pluri common shares representing 50% of ZEO’s issued and outstanding common stock immediately following closing. Pluri will grant defined rights to manufacturing technology and related know-how while retaining ownership of the underlying technology and intellectual property.
When is the Pluri and ZEO ScientifiX transaction expected to close?
Closing is expected in the fourth quarter of 2026, subject to negotiation of ancillary agreements, certain approvals and delivery of valuations, alongside customary closing conditions. The transaction does not require stockholder approval from either company.
Will Pluri consolidate ZEO ScientifiX’s financial results after closing?
Pluri expects to consolidate ZEO’s financial results into its financial statements following closing, subject to applicable accounting requirements.
What additional provisions does the Pluri and ZEO ScientifiX agreement include?
The agreement includes warrants, corporate governance and protective rights. It also includes customary representations and warranties, covenants and indemnifications by the parties.